| Name | Title | Contact Details |
|---|
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
Sydnexis Inc. is a clinical stage biopharmaceutical company based in San Diego. They are currently evaluating their patented eyedrop formulation, SYD 101, in a Phase 3 clinical trial to decrease myopia progression in children.
Waltz Pharmacy Inc is a Camden, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioScrip is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alliance Health Networks is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.